SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Turbo Lawyer who wrote (788)9/12/1997 8:48:00 AM
From: Henry Niman   of 2173
 
Here's the AMLN discussion in thestreet ( thestreet.com ):
"A deal with Johnson & Johnson would be noteworthy for its effects on Amylin
Pharmaceuticals (AMLN:Nasdaq), which has a big deal with J&J on its
compound, pramlintide. Two weeks ago, Amylin fell 43% after mixed results
in two studies of its drug in Type I and Type II patients. The company's
trials did not meet statistical significance in Type II patients, and
investors are concerned that the effect seen in the Type I patients wasn't
dramatic. If Ligand signs a deal with J&J, investors would take the move as
a sign that J&J wasn't thrilled with its Amylin alliance and might back off
from it. However, the future of diabetes treatment, as in cancer and AIDS,
may be in cocktail therapy, meaning that pramlintide may be useful in
combination with other drugs."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News